Valuation: Grifols SA

Market Cap 6.07B 6.82B 5.62B 5.12B 9.65B 648B 9.81B 67.58B 26.5B 338B 25.61B 25.07B 1,077B P/E 2026 *
13x
P/E 2027 * 9.96x
Enterprise Value 14.44B 16.25B 13.39B 12.18B 22.98B 1,542B 23.35B 161B 63.09B 805B 60.98B 59.68B 2,565B EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.73x
Free-Float
79.65%
Yield 2026 *
2.65%
Yield 2027 * 2.94%
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.18%+3.61%+35.16%+61.65% 437.88B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%

Financials

2026 *2027 *
Net sales 7.69B 8.65B 7.12B 6.48B 12.23B 821B 12.43B 85.63B 33.57B 428B 32.45B 31.76B 1,365B 8.16B 9.18B 7.57B 6.88B 12.99B 872B 13.2B 90.96B 35.66B 455B 34.47B 33.74B 1,450B
Net income 531M 597M 492M 448M 845M 56.66B 858M 5.91B 2.32B 29.57B 2.24B 2.19B 94.26B 700M 787M 649M 590M 1.11B 74.73B 1.13B 7.8B 3.06B 39B 2.96B 2.89B 124B
Net Debt 8.38B 9.42B 7.77B 7.06B 13.33B 894B 13.55B 93.34B 36.6B 467B 35.37B 34.62B 1,488B 8.07B 9.08B 7.48B 6.81B 12.85B 862B 13.05B 89.94B 35.26B 450B 34.08B 33.36B 1,434B
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Grifols SA